Loading...
Market
Which company will emerge as the next major competitor to Tezspire by end of 2025?
2
Resolution / Starting Odds
Sanofi • 25%
GSK • 25%
Regeneron • 25%
Other • 25%
Announcements from pharmaceutical companies and clinical trial results
Story
Amgen and AstraZeneca Report Positive Phase 3 WAYPOINT Results for Tezspire in CRSwNP, Meeting Primary Endpoints
Nov 8, 2024, 07:11 AM
Amgen and AstraZeneca have announced positive top-line results from their Phase 3 WAYPOINT trial evaluating Tezspire for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP). The trial met both co-primary endpoints, demonstrating a statistically significant reduction in nasal polyp size. This marks a significant advancement in treatment options for patients suffering from this condition. The companies' stocks, $AMGN and $AZN, are likely to be impacted by this development.
View original story
Similar markets
Sun Pharma • 25%
Dr. Reddy's Laboratories • 25%
Cipla • 25%
Other • 25%
Samsung • 25%
Amazon • 25%
Google • 25%
Other • 25%
Biogen • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Amazon • 25%
Google • 25%
Microsoft • 25%
Other • 25%
Tata Motors • 25%
Tata Steel • 25%
Tata Consultancy Services • 25%
Other • 25%
Apple • 25%
Microsoft • 25%
Amazon • 25%
No Major Response • 25%
Google • 25%
Bing • 25%
Perplexity AI • 25%
Other • 25%
Apple • 25%
Microsoft • 25%
Nvidia • 25%
Other • 25%
Blue Origin • 25%
Bytedance • 25%
Tesla • 25%
Other • 25%
Nvidia • 25%
Apple • 25%
Microsoft • 25%
Other • 25%
Align Technology • 25%
Henry Schein • 25%
Dentsply Sirona • 25%
Other • 25%
IndiGo • 25%
SpiceJet • 25%
Air India • 25%
Other • 25%